Sugi Predict

Sugi Predict / Compounds / SCHEMBL13137474

SCHEMBL13137474

SCHEMBL13137474

CC(C)(C)OC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.43
▸ ADORA1 P30542 5/20 0.42
▸ GBA1 P04062 1/20 0.41
▸ IDO1 P14902 1/20 0.40
▸ GLP1R P43220 5/20 0.40
▸ CA12 O43570 3/20 0.40
▸ CA1 P00915 3/20 0.40
▸ CA2 P00918 3/20 0.40
▸ CA9 Q16790 3/20 0.40
▸ SUCNR1 Q9BXA5 1/20 0.39
▸ MAOA P21397 1/20 0.38
▸ MAOB P27338 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13077420 0.97 MEN1 (0.44) MEN1GAAKMT2ATDP1ADORA1
SCHEMBL29679063 0.97 MEN1 (0.44) MEN1GAAKMT2ATDP1ADORA1
SCHEMBL9971647 0.97 MEN1 (0.44) MEN1GAAKMT2ATDP1ADORA1
SCHEMBL3486898 0.97 MEN1 (0.44) MEN1GAAKMT2ATDP1ADORA1
SCHEMBL23728812 0.94 MEN1 (0.49) MEN1GAAKMT2ATDP1GBA1
SCHEMBL13699512 0.94 MEN1 (0.49) MEN1GAAKMT2ATDP1GBA1
SCHEMBL25695638 0.94 MEN1 (0.49) MEN1GAAKMT2ATDP1GBA1
SCHEMBL21071644 0.94 MEN1 (0.49) MEN1GAAKMT2ATDP1GBA1
SCHEMBL21069640 0.94 MEN1 (0.49) MEN1GAAKMT2ATDP1GBA1
SCHEMBL1261192 0.94 MEN1 (0.49) MEN1GAAKMT2ATDP1GBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114805543-B Synthesis method of cable Ma Lutai side chain 四川普康药业有限公司 2023-05-19 — — CN claimed
CN-114805543-A Synthesis method of somaglutide side chain 四川普康药业有限公司 2022-07-29 — — CN claimed
EP-4602064-B1 METHOD OF MANUFACTURING A PEPTIDE WITH A LYSINE DERIVATIVE BACHEM HOLDING AG (CH) 2026-05-13 — — EP disclosed
EP-4602064-A1 METHOD OF MANUFACTURING A PEPTIDE WITH A LYSINE DERIVATIVE Bachem Holding AG (CH) 2025-08-20 — — EP disclosed
CN-120209075-A Method for preparing side chain pentapeptide of polypeptide medicament at low temperature 苏州特瑞药业股份有限公司 2025-06-27 — — CN disclosed
CN-120172882-A Method for synthesizing Boc-AEEA-AEEA-OH 吉尔多肽生物制药(大连市)有限公司 2025-06-20 — — CN disclosed
CN-120172882-A Method for synthesizing Boc-AEEA-AEEA-OH 吉尔多肽生物制药(大连市)有限公司 2025-06-20 — — CN disclosed
WO-2025078040-A1 LYSINE SALT AND METHOD OF MANUFACTURING A LYSINE DERIVATIVE BACHEM HOLDING AG (CH) 2025-04-17 — — WO disclosed
CN-119638592-A Preparation method of cable-marlutide side chain 苏州昊帆生物股份有限公司 2025-03-18 — — CN disclosed
US-20250019410-A1 PROCESS FOR THE PREPARATION OF TIRZEPATIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2025-01-16 — — US disclosed
US-12178842-B2 PCSK9 antagonist compounds MERCK SHARP & DOHME LLC (US) 2024-12-31 — — US disclosed
CN-113444164-B Solid-phase synthesis method of Somalutide 台州吉诺生物科技有限公司 2022-07-19 — — CN disclosed
EP-4021919-A1 PCSK9 ANTAGONIST COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2022-07-06 — — EP disclosed
US-20210069288-A1 PCSK9 ANTAGONIST COMPOUNDS MERCK SHARP & DOHME LLC 2021-03-11 — — US disclosed
EP-3398933-B1 METHOD FOR PREPARING LONG-CHAIN COMPOUND HYBIO PHARMACEUTICAL CO LTD (CN) 2020-12-16 — — EP disclosed
US-10399927-B2 Method for preparing long-chain compound Hybio Pharmaceutical Co., Ltd. (CN) 2019-09-03 — — US disclosed
EP-3245513-B1 MACROMOLECULAR CONJUGATES FOR ISOLATION, IMMOBILIZATION AND VISUALIZATION OF PROTEINS USTAV ORGANICKE CHEMIE A BIOCHEMIE AKADEMIE VED CESKE REPUBLIKY V V I (CZ) 2019-07-10 — — EP disclosed
WO-2016112882-A2 MACROMOLECULAR CONJUGATES FOR ISOLATION, IMMOBILIZATION AND VISUALIZATION OF PROTEINS USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2016-07-21 — — WO disclosed
US-20100221749-A1 THREE-FUNCTIONAL PSEUDO-PEPTIDIC REAGENT, AND USES AND APPLICATIONS THEREOF UNIVERSITE DE ROUEN 2010-09-02 — — US disclosed
US-20100221749-A1 THREE-FUNCTIONAL PSEUDO-PEPTIDIC REAGENT, AND USES AND APPLICATIONS THEREOF UNIVERSITE DE ROUEN 2010-09-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10399927-B2 Method for preparing long-chain compound ORC3, OR10J3, ORMDL3 MEN1 3200/4885GAA 4201/4885KMT2A 3825/4885
US-20210069288-A1 PCSK9 ANTAGONIST COMPOUNDS PCSK9, PCSK7, PCSK6 MEN1 1646/4885GAA 482/4885KMT2A 1433/4885
US-12178842-B2 PCSK9 antagonist compounds PCSK9, PCSK7, PCSK6 MEN1 1646/4885GAA 482/4885KMT2A 1433/4885
US-20250019410-A1 PROCESS FOR THE PREPARATION OF TIRZEPATIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SYK, TREH, QDPR MEN1 1653/4885GAA 108/4885KMT2A 2758/4885
US-20100221749-A1 THREE-FUNCTIONAL PSEUDO-PEPTIDIC REAGENT, AND USES AND APPLICATIONS THEREOF DNPEP, PEPD, LNPEP MEN1 2481/4885GAA 392/4885KMT2A 3483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.